CN1646157B - 多重性和多价性蛋内dna疫苗 - Google Patents

多重性和多价性蛋内dna疫苗 Download PDF

Info

Publication number
CN1646157B
CN1646157B CN038080001A CN03808000A CN1646157B CN 1646157 B CN1646157 B CN 1646157B CN 038080001 A CN038080001 A CN 038080001A CN 03808000 A CN03808000 A CN 03808000A CN 1646157 B CN1646157 B CN 1646157B
Authority
CN
China
Prior art keywords
dna
virus
multiplex
dna vaccine
disease virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN038080001A
Other languages
English (en)
Chinese (zh)
Other versions
CN1646157A (zh
Inventor
郭村勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schweitzer Chemical Corp
Original Assignee
Schweitzer Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schweitzer Chemical Corp filed Critical Schweitzer Chemical Corp
Publication of CN1646157A publication Critical patent/CN1646157A/zh
Application granted granted Critical
Publication of CN1646157B publication Critical patent/CN1646157B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN038080001A 2002-03-08 2003-03-06 多重性和多价性蛋内dna疫苗 Expired - Fee Related CN1646157B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36254702P 2002-03-08 2002-03-08
US60/362,547 2002-03-08
US10/377,718 US7029681B2 (en) 2002-03-08 2003-03-04 Multiple and multivalent DNA vaccines in ovo
US10/377,718 2003-03-04
PCT/US2003/006811 WO2003075843A2 (en) 2002-03-08 2003-03-06 Multiple and multivalent dna vaccines in ovo

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910212389A Division CN101703770A (zh) 2002-03-08 2003-03-06 多价性蛋内dna疫苗

Publications (2)

Publication Number Publication Date
CN1646157A CN1646157A (zh) 2005-07-27
CN1646157B true CN1646157B (zh) 2011-03-02

Family

ID=27807969

Family Applications (2)

Application Number Title Priority Date Filing Date
CN038080001A Expired - Fee Related CN1646157B (zh) 2002-03-08 2003-03-06 多重性和多价性蛋内dna疫苗
CN200910212389A Pending CN101703770A (zh) 2002-03-08 2003-03-06 多价性蛋内dna疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200910212389A Pending CN101703770A (zh) 2002-03-08 2003-03-06 多价性蛋内dna疫苗

Country Status (10)

Country Link
US (1) US7029681B2 (enExample)
EP (1) EP1490105B1 (enExample)
JP (2) JP4999258B2 (enExample)
CN (2) CN1646157B (enExample)
AU (1) AU2003216531B2 (enExample)
BR (1) BRPI0308365B1 (enExample)
CA (1) CA2478081C (enExample)
IL (2) IL163859A0 (enExample)
MX (1) MXPA04008692A (enExample)
WO (1) WO2003075843A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037506B2 (en) * 2002-03-08 2006-05-02 Schweltzer Chemical Corporation Ltd. Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry
US8956628B2 (en) * 2007-12-13 2015-02-17 Zoetis Products Llc Bacteriophage preparations and method of use thereof
BR112014008161A2 (pt) 2011-10-21 2017-04-11 Intervet Int Bv vírus da doença de marek não patogênico recombinante, método para a preparação do mesmo, molécula do ácido nucleico, célula hospedeira, vacina para aves domésticas, método para a preparação de uma vacina, uso de um vírus da doença de marek não patogênico recombinante, e, método de vacinação de aves domésticas
US8932604B2 (en) 2011-10-21 2015-01-13 Intervet Inc. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
EP2644702A1 (en) * 2012-03-30 2013-10-02 Ceva Sante Animale Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
CN102895660B (zh) * 2012-10-25 2014-04-23 中国兽医药品监察所 一种鸭病毒性肝炎二价灭活疫苗
US9950059B2 (en) 2014-02-25 2018-04-24 The United States Of America, As Represented By The Secretary Of Agriculture. Immunogenic composition
CN110295149B (zh) * 2019-06-24 2022-06-24 四川农业大学 一种突变株3型鸭甲肝病毒ch-p60-117c株及构建方法
US11299517B2 (en) * 2020-04-15 2022-04-12 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant vaccine against Marek's disease and Newcastle disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693530A (en) * 1994-01-11 1997-12-02 Cornell Research Foundation, Inc. Marek's disease virus nucleotide sequence and methods of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US182241A (en) * 1876-09-12 Improvement in animal-traps
US3575A (en) * 1844-05-06 Improvement
US4458630A (en) 1982-06-22 1984-07-10 The United States Of America As Represented By The Secretary Of Agriculture Disease control in avian species by embryonal vaccination
EP0434747B1 (en) * 1988-09-13 1999-05-19 Merial RECOMBINANT VACCINES BASED ON THE gB-PROTEIN OF MAREK'S DISEASE VIRUS
ATE200735T1 (de) 1989-10-02 2001-05-15 Univ Arkansas Impfstoffkonjugat
US5397568A (en) 1989-10-02 1995-03-14 Whitfill; Craig E. Method of treating infectious bursal disease virus infections
US5056464A (en) 1990-01-18 1991-10-15 Embrex, Inc. Automated injection system for avian embryos with advanced fluid delivery system
US5595912A (en) 1990-05-04 1997-01-21 University Of Maryland College Park Specific DNA and RNA sequences associated with US IBDV variants, vector carrying DNA sequences, host carrying cloned vector, deduced amino acid sequences, vaccine and method of vaccination
ZA924203B (en) 1991-06-18 1993-03-31 Akzo Nv Coccidiosis poultry vaccine
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
JPH06141853A (ja) * 1992-10-30 1994-05-24 Chemo Sero Therapeut Res Inst 組換え鶏伝染性喉頭気管炎ウイルス及びその製法
WO1994019014A1 (en) * 1993-02-26 1994-09-01 Syntro Corporation Recombinant fowlpox virus s-fpv-043 and uses thereof
CA2192994A1 (en) 1994-06-20 1995-12-28 Henry D. Stone In ovo immunization of avian embryos with oil-emulsion vaccines
US5817320A (en) 1994-06-20 1998-10-06 The United States Of America As Represented By The Secretary Of The Agriculture In ovo immunization of avian embryos with oil-emulsion vaccines
JPH08116976A (ja) * 1994-10-20 1996-05-14 Chemo Sero Therapeut Res Inst 免疫用核酸調製物およびこれを用いた免疫方法
EP0837929A2 (en) 1995-07-07 1998-04-29 Nippon Zeon Co., Ltd. Marek's disease virus genes and their use in vaccines for protection against marek's disease
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
US5699751A (en) 1996-10-02 1997-12-23 Embrex, Inc. Method and apparatus for in ovo injection
US6048535A (en) * 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
JP4091152B2 (ja) * 1997-09-19 2008-05-28 財団法人化学及血清療法研究所 金コロイドを含む核酸調製物
UY25347A1 (es) 1998-01-12 1999-05-14 Embrex Inc Procedimiento de inyeccion multiple para el tratamiento de embriones aviarios in ovo, y aparato automatizado para la inyeccion in ovo.
US6286455B1 (en) 1998-01-12 2001-09-11 Embrex, Inc. Automated in ovo injection apparatus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693530A (en) * 1994-01-11 1997-12-02 Cornell Research Foundation, Inc. Marek's disease virus nucleotide sequence and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GAGIC M. et al.IN OVO VACCINATION OF SPECIFIC-PATHOGEN-FREE CHICKENS WITH VACCINES CONTANING MULTIPLE ANTIGENS.《avian disease 》.1999,第43卷293-301. *
REDDY S.K. ET AL..PROTECTIVE EFFICACY OF A RECOMBINANT HERPESVIRUS OF TURKESYS AS AN IN OVO VACCINE AGAINSE NEWCASTLE AND MAREK"S DISEASE IN SPECIFIC-PATHOGEN-FREE CHICKENS.<VACCINE>.1996,第14卷469-477. *
SHARMA J. M..EMBRYO VACINATION OF SPECIFIC-PATHOGEN-FREE CHINCKENS WITH INFECTIOUS BURSAL DISEASE VIRUS:TISSUE DISTRIBUTION OF THE VACCINE VIRUS AND PROTECTION OF HATCHED CHICKENS AGAINST DISEASE.<AVIAN DISEASE>.1986,第30卷776-780. *
sharma j.M..EMBRYO VACCINATION WITH INFECTIOUS BURSAL DISEASE VIRUS ALONE OR IN COMBINATION WITH MAREK"S DISEASE VACINE.《AVIAN DISEASE》.1985,第29卷1155-1169. *

Also Published As

Publication number Publication date
EP1490105A4 (en) 2006-04-19
JP2005519943A (ja) 2005-07-07
US7029681B2 (en) 2006-04-18
EP1490105B1 (en) 2013-10-02
IL163859A (en) 2010-05-17
AU2003216531B2 (en) 2006-11-30
JP2009203242A (ja) 2009-09-10
JP4999258B2 (ja) 2012-08-15
CN1646157A (zh) 2005-07-27
CA2478081C (en) 2011-04-19
AU2003216531A1 (en) 2003-09-22
EP1490105A2 (en) 2004-12-29
US20030175291A1 (en) 2003-09-18
MXPA04008692A (es) 2005-02-24
IL163859A0 (en) 2005-12-18
WO2003075843A3 (en) 2004-07-22
WO2003075843A2 (en) 2003-09-18
CA2478081A1 (en) 2003-09-18
BRPI0308365B1 (pt) 2016-12-27
BR0308365A (pt) 2005-09-06
CN101703770A (zh) 2010-05-12

Similar Documents

Publication Publication Date Title
CN102405058B (zh) 用于免疫接种水禽物种的重组禽疱疹病毒载体和疫苗
JP6505593B2 (ja) 多価組換型鳥ヘルペスウイルス及び鳥類を免疫化するためのワクチン
RU2593950C2 (ru) Рекомбинантный непатогенный mdv-вектор, обеспечивающий полиспецифический иммунитет
CZ300760B6 (cs) cDNA ptacího paramyxoviru, zpusob její prípravy, její infekcní kopie a vakcína je obsahující
US20230340028A1 (en) Modified s1 subunit of the coronavirus spike protein
JP2009203242A (ja) インビボ（ｉｎｖｉｖｏ）マルチプルｄｎａワクチンと多価ｄｎａワクチン
JP6210998B2 (ja) ベクターワクチンおよび生ワクチンの併用による感染症の予防方法
US11224649B2 (en) 4/91 IBV vaccine with heterologous spike protein
US11696947B2 (en) H52 IBV vaccine with heterologous spike protein
US11090377B2 (en) Avian reovirus vaccines
CN107771216B (zh) 重组mdv1及其用途
JPH11507241A (ja) 組換え鶏痘ウイルスおよびその使用
Ali et al. A mini-review on Newcastle disease virus in Egypt, with particular references to common vaccines and their development
US7037506B2 (en) Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry
KR20200051499A (ko) H9 헤마글루티닌을 포함하는 뉴캐슬병 재조합 벡터 및 이로부터 제조된 재조합 바이러스
JP2002095485A (ja) 広域スペクトルの伝染性ファブリキウス嚢病ウイルスワクチン
WO2025199518A2 (en) Enzymes for depletion of glutamine
BR112021022651B1 (pt) Proteína spike do coronavírus aviário, partícula viral, coronavírus aviário, composições imunogênicas, método para cultivar coronavírus aviário e ibv (vírus da bronquite infecciosa)
JP2001086983A (ja) 家禽用ワクチン
Ahmad Embryo vaccination in chickens and turkeys with Newcastle disease virus and avian adenovirus type-II

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110302

Termination date: 20210306

CF01 Termination of patent right due to non-payment of annual fee